….Results achieved over the last three years of testing the company is now preparing a submission to enter into phase one and two human clinical trials. Additional studies will be expanded to include whole organ transplantation.
.…AAGP™ is manufactured at facilities in North America, Europe, and Asia for shipment worldwide.
….ProtoKinetix anticipates that its future lies as a value-adding compound in two prime areas:
(1)..For challenges in regenerative medicine and the stresses resulting from the harvesting, purification, expansion, cryopreservation, and re-engraftment of cells.
(2)..For the treatment and cures of such inflammation-related conditions as diabetes, arthritis, neural-related diseases.